Prosolv tech in API development pact
JRS Pharma has entered into a collaboration with US firm CoreRX to develop co-processed active pharmaceutical ingredients (APIs) using JRS's high functionality excipient technology, Prosolv
Archives for June 11, 2007
TTP celebrates 20th Anniversary
UK technology expert The Technology Partnership (TTP) celebrates its 20th birthday this year with its focus on innovation stronger than ever.
3M sells another chunk of pharma biz
Diverse manufacturer 3M has agreed to sell off another chunk of its pharmaceuticals business, fourteen months after it decided to give up on the 'very competitive' industry.
Taiwan to use new plasma protein extraction technology
Taiwan looks to benefit from a new alliance with Canada-based ProMetic BioTherapeutics, which will provide a proprietary manufacturing process to extract plasma proteins for drugs.
Hunting for drug candidates on Kinase SARfari
BioFocus DPI has released a new informatics system that can combine chemical and biological data from various sources to optimise protein kinase inhibitor candidate selection.
New website urges ethanol policy review
A food industry coalition has launched a website designed to provide information on the impact of the US policy on ethanol of processors and consumers.
Asterand outlines action for profitability
Asterand has announced a restructure and changes to its operational model in a bid to grasp hold of profitability.
Kurve Technology and Schering-Plough expand agreement
Schering-Plough and Kurve Technology have signed a new agreement involving Kurve's nasal drug delivery device, which follows on the heals of a partnership formed between the two companies last year.
Applikon releases 'generic' bioreactor controller
Applikon Biotechnology has launched a new bioreactor controller, the i-ControlXL, that has been designed to work with reactors of any size, from any supplier.
Patheon steps up 'damage control' over Puerto Rico
After dismal second quarter results Patheon is stepping up its resolve for 'damage control' and indicated that further cutbacks at its problematic Puerto Rico plant are imminent.
GSK reveals details of $2bn antibody
GlaxoSmithKline (GSK) outlined more details on the mechanism of its anticancer drug ofatumumab - an antibody that was the subject of the biggest ever pharma licensing deal.